Login/Register

News

Lotus Pharmaceutical: 2025 Targets Intact; Alvogen US Acquisition to Close by Year-End

At its recent earnings call, Lotus Pharmaceutical reaffirmed its 2025 goals: 5–6% revenue growth, ~60% gross margin, and an operating margin exceeding 30%.

Read more
Nov 26, 2025
Nov 26, 2025
Nov 26, 2025
Nov 26, 2025
Nov 25, 2025
Nov 25, 2025
Nov 25, 2025
Nov 25, 2025
Nov 25, 2025